Overview
- Contributes to a careful knowledge of the biochemistry, pathophysiology and clinics of cancer biomarkers
- Promotes an optimal clinical use of cancer biomarkers
- Facilitates the understanding of the real diagnostic index of old and new cancer biomarkers
- Fosters a rational clinical approach to the diagnosis and prognosis of cancer
- Includes supplementary material: sn.pub/extras
Part of the book series: Advances in Experimental Medicine and Biology (AEMB, volume 867)
Access this book
Tax calculation will be finalised at checkout
Other ways to access
Table of contents (21 chapters)
-
Front Matter
-
Generality
-
Front Matter
-
-
Tumor Markers – A Critical Revision: Enzymes
-
Front Matter
-
-
Tumor Markers – A Critical Revision: Hormones
-
Front Matter
-
-
Tumor Markers – A Critical Revision: Oncofetal Proteins
-
Front Matter
-
-
Tumor Markers – A Critical Revision: Cytokeratins
-
Front Matter
-
-
Tumor Markers – A Critical Revision: Carbohydrate Markers
-
Front Matter
-
Keywords
About this book
At present there are a growing number of biomolecules under investigation to understand their potential role as cancer biomarker for diagnostic, prognostic and therapeutic purposes. Intriguingly, the state of art on cancer biomarkers research shows interesting and promising results together to clamorous failures. Also from a clinical point of view, there are contradictory results on routine clinical use of the present cancer biomarkers. Some patients may be simply monitored in their course by a periodic blood sample, but sometimes this monitoring shows dramatic limits. A lot of patients show serious and extensive relapses without significant change in serum concentrations of biomarkers tested. Often the physician who should utilize these biomarker does not entirely know their limits and the total potential applications as well and sometimes this knowledge is influenced by economical and marketing strategies. This limited and “polluted” knowledge may have dramatic consequences for patient. The aim of this book is to diffuse all aspects of cancer biomarkers, from their biochemical peculiarities to all clinical implications by passing through their physiology and pathophysiology.
This critical approach towards old and new cancer biomarkers should foster a deepened and useful understanding of the diagnostic and prognostic index of these fundamental parameters of laboratory medicine and in the same time facilitating the research of new and more sensitive-specific signals of the cancer cell proliferation.
Editors and Affiliations
Bibliographic Information
Book Title: Advances in Cancer Biomarkers
Book Subtitle: From biochemistry to clinic for a critical revision
Editors: Roberto Scatena
Series Title: Advances in Experimental Medicine and Biology
DOI: https://doi.org/10.1007/978-94-017-7215-0
Publisher: Springer Dordrecht
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature B.V. 2015
Hardcover ISBN: 978-94-017-7214-3Published: 16 November 2015
Softcover ISBN: 978-94-024-0420-3Published: 23 August 2016
eBook ISBN: 978-94-017-7215-0Published: 03 November 2015
Series ISSN: 0065-2598
Series E-ISSN: 2214-8019
Edition Number: 1
Number of Pages: IX, 372
Number of Illustrations: 6 b/w illustrations, 21 illustrations in colour
Topics: Cancer Research, Oncology, Pharmacology/Toxicology